|
| Exchange Received Time 18/08/2017 17:23:11 Exchange Disseminated Time 18/08/2017 17:23:20 Time Taken 00:00:09 | Dear Sir,
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 18 August 2017 had approved the Un-audited Financial Results of the Company for the quarter ended 30 June 2017. Further the Board took note of increase in manufacturing capacity of the Ibuprofen from 6200 TPA to 7200 TPA by conversion of existing multipurpose plant.
Please find enclosed herewith the following:
1. Un-audited Financial Results for the quarter ended 30 June 2017
2. Independent Auditors' Review Report on the Un-audited Financial Results for the Quarter ended 30 June 2017
Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 05:00 p.m.
|
|
|